Ranega 23 mg FC tablets
PDF Leaflet Revision Date: 21 November 2024
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of HIV-1 infection in adults aged 18 years and older.
Dosage (summary)
One tablet orally once daily, without regard to food.
Special Populations
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy and lactation; potential risk of neural tube defects.
Key Drug Interactions
- Rifampicin decreases dolutegravir levels
- Trimethoprim increases lamivudine levels
Contraindications
- Hypersensitivity to components
- Uncontrolled renal failure
- Pregnancy
- Moderate and severe hepatic impairment
Common side effects
- Depression
- Nausea
- Fatigue
- Headache
- Rash
Counselling Points
- Monitor for signs of depression
- Avoid breastfeeding
- Use effective contraception in women of childbearing age
Serious warnings
- Lactic acidosis
- Severe hepatomegaly
- Immune reconstitution inflammatory syndrome
Important Disclaimer
The Ranega 23 mg FC tablets professional information leaflet below is the property of Viatris Healthcare and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
